3D conformal radiation therapy

RADIATION2 trials

Sponsors

Emory University, Biogen

Conditions

Bladder CancerBreast CancerSquamous Cell Carcinoma of the BladderStage III Bladder CancerStage IV Bladder CancerTransitional Cell Carcinoma of the Bladder

Phase 2

RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE

CompletedNCT02142959

BiogenBreast Cancer

Start: 2014-06-30End: 2015-04-30Updated: 2025-06-03

Unknown Phase

Adjuvant Radiation for High Risk Bladder Cancer

TerminatedNCT01954173

Emory UniversityBladder Cancer, Squamous Cell Carcinoma of the Bladder, Stage III Bladder Cancer +2

Start: 2013-07-22End: 2021-09-20Updated: 2022-03-02

Related Papers

Bone Marrow Suppression during Postoperative Radiation for Bladder Cancer and Comparative Benefit of Proton Therapy-Phase 2 Trial Secondary Analysis.

2021-07-066 citations

Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteers.

2015-07-1424 citations